New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these findings, a clear link has yet to be established, and much of the evidence remains ...

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

Diabetic retinopathy is the leading cause of blindness in working-age adults in the U.S. and is a complication of diabetes.

Diabetic retinopathy may not cause any symptoms in its early stages, but as the disease progresses, you may experience changes to your vision, including: Blurred vision Vision that fluctuates ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...